161 related articles for article (PubMed ID: 12850996)
21. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
22. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
23. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
24. Bubble babies and bathwater.
Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
[No Abstract] [Full Text] [Related]
25. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
26. Safety and efficacy in retrovirally modified haematopoietic cell therapy.
Li Z; Modlich U; Baum C
Best Pract Res Clin Haematol; 2004 Sep; 17(3):493-503. PubMed ID: 15498719
[TBL] [Abstract][Full Text] [Related]
27. [Hematopoietic malignancies and gene therapy].
Ozawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
[TBL] [Abstract][Full Text] [Related]
28. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
[TBL] [Abstract][Full Text] [Related]
29. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
30. Regulators split on gene therapy as patient shows signs of cancer.
Check E
Nature; 2002 Oct; 419(6907):545-6. PubMed ID: 12374936
[No Abstract] [Full Text] [Related]
31. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
32. Gene therapy. RAC's advice: proceed with caution.
Kaiser J
Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
[No Abstract] [Full Text] [Related]
33. Murine leukemia induced by retroviral gene marking.
Li Z; Düllmann J; Schiedlmeier B; Schmidt M; von Kalle C; Meyer J; Forster M; Stocking C; Wahlers A; Frank O; Ostertag W; Kühlcke K; Eckert HG; Fehse B; Baum C
Science; 2002 Apr; 296(5567):497. PubMed ID: 11964471
[No Abstract] [Full Text] [Related]
34. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
35. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
36. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
37. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
Kaiser J
Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
[No Abstract] [Full Text] [Related]
38. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
39. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.
Mostoslavsky G; Kotton DN; Fabian AJ; Gray JT; Lee JS; Mulligan RC
Mol Ther; 2005 Jun; 11(6):932-40. PubMed ID: 15922964
[TBL] [Abstract][Full Text] [Related]
40. Of mice and men: the tale of two therapies.
Hawley RG; Sobieski DA
Stem Cells; 2002; 20(4):275-8. PubMed ID: 12110695
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]